The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer.
I. R. MacPherson
No relevant relationships to disclose
D. Bissett
No relevant relationships to disclose
R. D. Petty
No relevant relationships to disclose
B. Tait
No relevant relationships to disclose
L. M. Samuel
No relevant relationships to disclose
J. MacDonald
No relevant relationships to disclose
M. Smith
No relevant relationships to disclose
J. A. Birse-Archbold
Employment or Leadership Position - CXR Biosciences
Stock Ownership - CXR Biosciences
A. L. Barnett
Employment or Leadership Position - CXR Biosciences
Stock Ownership - CXR Biosciences
C. R. Wolf
Employment or Leadership Position - CXR Biosciences
Stock Ownership - CXR Biosciences
C. R. Elcombe
Employment or Leadership Position - CXR Biosciences
Stock Ownership - CXR Biosciences
A. Jeynes-Ellis
Consultant or Advisory Role - CXR Biosciences
T. R. J. Evans
Research Funding - CXR Biosciences